Beyond the Small Molecule: Characterizing Peptide, Protein, and Nucleic Acid Therapeutics
The rapid growth of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of diabetes and obesity has increased the need for robust analytical methods capable of separating and quantifying closely related impurities. These impurities, which can arise from synthesis or degradation pathways, often differ from the active pharmaceutical ingredient (API) by only a single amino acid substitution, oxidation, deamidation, truncation, or stereochemical change.